Journal article
Budesonide/formoterol maintenance and reliever therapy versus conventional best practice
Abstract
Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) reduces asthma exacerbations and symptoms versus fixed-dose regimens plus short-acting beta(2)-agonists (SABA) in double-blind trials. Information is lacking regarding its effectiveness versus conventional best practice (CBP). This pooled analysis of six 6-month, randomized, open-label studies examined asthma control and exacerbation risk in asthmatics (aged> or =12 …
Authors
Demoly P; Louis R; Søes-Petersen U; Naya I; Carlsheimer Å; Worth H; Almeida J; Sears MR
Journal
Respiratory Medicine, Vol. 103, No. 11, pp. 1623–1632
Publisher
Elsevier
Publication Date
November 2009
DOI
10.1016/j.rmed.2009.07.018
ISSN
0954-6111
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdrenergic beta-AgonistsAdultAgedAged, 80 and overAsthmaBronchodilator AgentsBudesonideChildDouble-Blind MethodDrug Therapy, CombinationEthanolaminesFemaleFormoterol FumarateHumansMaleMiddle AgedPractice Guidelines as TopicRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeYoung Adult